Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili, Ling Huang, Hua Li, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 289
Closed Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter, Greg A. Lazar
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 3, pp. 197-223
Closed Access | Times Cited: 671
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella, David M. Barrett, Saad S. Kenderian, et al.
Journal of Clinical Investigation (2016) Vol. 126, Iss. 10, pp. 3814-3826
Open Access | Times Cited: 515
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, et al.
Blood (2020) Vol. 137, Iss. 6, pp. 751-762
Open Access | Times Cited: 262
Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma, Yicheng Mo, Menglin Tang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 235
Emerging agents and regimens for AML
Hongtao Liu
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 192
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
Takahiro Ishiguro, Yuji Sano, Shunichiro Komatsu, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 410
Open Access | Times Cited: 178
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Marco Ruella, Michael Klichinsky, Saad S. Kenderian, et al.
Cancer Discovery (2017) Vol. 7, Iss. 10, pp. 1154-1167
Open Access | Times Cited: 175
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
Jayakumar Vadakekolathu, Mark D. Minden, Tressa Hood, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 546
Open Access | Times Cited: 171
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Xin He, Zijie Feng, Jian Ma, et al.
Blood (2020) Vol. 135, Iss. 10, pp. 713-723
Open Access | Times Cited: 159
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 138
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 96
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 9, pp. 1296-1306
Open Access | Times Cited: 65
Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
Muneera Al-Hussaini, Michael P. Rettig, Julie Ritchey, et al.
Blood (2015) Vol. 127, Iss. 1, pp. 122-131
Open Access | Times Cited: 164
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian, Saad S. Kenderian, Feng Shen, et al.
Blood (2017) Vol. 129, Iss. 17, pp. 2395-2407
Open Access | Times Cited: 159
Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success
Amar Desai, Yan Yan, Stanton L. Gerson
Stem Cells Translational Medicine (2018) Vol. 8, Iss. 1, pp. 75-81
Open Access | Times Cited: 159
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez, Challice L. Bonifant, Stephen Gottschalk
Blood (2017) Vol. 131, Iss. 1, pp. 30-38
Open Access | Times Cited: 157
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun, Gregory E. Jones, Sharlene Adams, et al.
Blood Advances (2018) Vol. 2, Iss. 8, pp. 848-858
Open Access | Times Cited: 156
Bispecific antibody based therapeutics: Strengths and challenges
Archana Thakur, Manley Huang, Lawrence G. Lum
Blood Reviews (2018) Vol. 32, Iss. 4, pp. 339-347
Closed Access | Times Cited: 149
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R. Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.
Blood (2016) Vol. 129, Iss. 5, pp. 609-618
Open Access | Times Cited: 143
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa, Elvira Pelosi, Germana Castelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1358-1358
Open Access | Times Cited: 130
Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
Julia Sung, Joy Pickeral, Liqin Liu, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 11, pp. 4077-4090
Open Access | Times Cited: 128
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 128
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Zhanhong Wu, Nai‐Kong V. Cheung
Pharmacology & Therapeutics (2017) Vol. 182, pp. 161-175
Open Access | Times Cited: 125
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Blood Advances (2020) Vol. 4, Iss. 20, pp. 5011-5024
Open Access | Times Cited: 123
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
Derek D. Sloan, Chia‐Ying K. Lam, Alivelu Irrinki, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 11, pp. e1005233-e1005233
Open Access | Times Cited: 92
Page 1 - Next Page

Scroll to top